Expand IVVD Menu
IVVD MENU

IVVD Latest Press Releases

-- July 6, 2026 --

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA and Provides an Update on Next Steps with the U.S. FDA Globe Newswire 7:01 AM

-- July 2, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- June 29, 2026 --

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer Globe Newswire 7:00 AM

-- June 16, 2026 --

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine Globe Newswire 7:01 AM

-- June 9, 2026 --

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration Globe Newswire 7:01 AM

-- June 3, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- June 1, 2026 --

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID Globe Newswire 7:01 AM

-- May 27, 2026 --

Invivyd to Participate in Upcoming Investor Events Globe Newswire 7:01 AM

-- May 14, 2026 --

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:01 AM

-- May 11, 2026 --

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination Globe Newswire 7:01 AM

-- May 7, 2026 --

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 Globe Newswire 7:01 AM

-- May 5, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- April 20, 2026 --

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit Globe Newswire 7:01 AM

-- April 9, 2026 --

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles Globe Newswire 7:01 AM

-- April 7, 2026 --

Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health Globe Newswire 7:01 AM

-- April 6, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- March 30, 2026 --

Invivyd Announces Presentation at the World Vaccine Congress Washington Globe Newswire 4:05 PM

-- March 5, 2026 --

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates Globe Newswire 7:03 AM
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer Globe Newswire 7:01 AM

-- March 2, 2026 --

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 Globe Newswire 4:10 PM
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- February 24, 2026 --

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies Globe Newswire 7:01 AM
Market Data Delayed 15 Minutes